Last reviewed · How we verify
PEG Asparaginase at two weeks interval
PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.
PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine. Used for Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy.
At a glance
| Generic name | PEG Asparaginase at two weeks interval |
|---|---|
| Also known as | Oncaspar (PEG-Asparaginase) |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Enzyme (asparaginase) |
| Target | Asparagine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Leukemic blasts, particularly in acute lymphoblastic leukemia (ALL), are dependent on exogenous asparagine for protein synthesis and cannot produce sufficient amounts endogenously. By depleting circulating asparagine, the drug selectively inhibits protein synthesis in leukemic cells while sparing normal cells that can synthesize asparagine. PEGylation extends the drug's half-life and reduces immunogenicity compared to native asparaginase.
Approved indications
- Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy
Common side effects
- Hypersensitivity reactions
- Pancreatitis
- Hepatotoxicity
- Coagulopathy/thrombosis
- Nausea and vomiting
- Hyperglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: